FIELD: medicine.
SUBSTANCE: invention relates to a method for the treatment of NASH-associated liver cancer, which includes the administration of pharmaceutically effective amount of 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridine-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl]urea (compound C) or its pharmaceutically acceptable salt to a person or animal in need of it.
EFFECT: new method is developed for the treatment of NASH-associated liver cancer by means of prostaglandin E2 receptor 4 (EP4) antagonist, which is a compound C, which can be used in medicine.
4 cl, 8 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER | 2017 |
|
RU2717331C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2015 |
|
RU2708374C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| NEW APPROACH TO TREATING CANCER WITH APPLICATION OF IMMUNOMODULATION | 2016 |
|
RU2711380C2 |
| PROTEINS BINDING PROSTAGLANDIN E2 AND USING THEM | 2009 |
|
RU2559525C2 |
| COMBINATION THERAPY WITH A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | 2018 |
|
RU2796863C2 |
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO PD-1 AXIS AND TIGIT INHIBITORS | 2014 |
|
RU2702108C2 |
| REDUCTION OF TUMOR MASS BY INJECTING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | 2017 |
|
RU2745195C2 |
| METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY | 2017 |
|
RU2755903C2 |
